The resurgence of platinum-based cancer chemotherapy

  title={The resurgence of platinum-based cancer chemotherapy},
  author={Lloyd R. K{\`e}lland},
  journal={Nature Reviews Cancer},
  • L. Kèlland
  • Published 1 August 2007
  • Biology
  • Nature Reviews Cancer
The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s represent a major landmark in the history of successful anticancer drugs. Although carboplatin — a second-generation analogue that is safer but shows a similar spectrum of activity to cisplatin — was introduced in the 1980s, the pace of further improvements slowed for many years. However, in the past several years interest in platinum drugs has increased. Key developments include the… 
Understanding and Improving Platinum Anticancer Drugs
Cell-based assays reveal altered cellular uptake properties and a cancer cell-killing profile different from those of established platinum drugs, and Mechanistic work, including a crystal structure analysis of platinum-modified DNA in the active site of RNA polymerase II, is discussed.
Platinum drug distribution in cancer cells and tumors.
Alice Klein's research focuses on developing novel platinum(IV)-intercalator hybrid complexes and investigating their potential as antitumour agents in cells and the search for new platinum anticancer drugs is driven by the need to overcome the side effects and limited tumor penetration of existing platinum agents.
Novel platinum compounds and nanoparticles as anticancer agents.
This review summarizes the published patent applications on the novel platinum anticancer compounds from 2012 to 2017 and summarizes the astonishing achievement of these drugs.
Understanding and improving platinum anticancer drugs--phenanthriplatin.
Cell-based assays reveal altered cellular uptake properties and a cancer cell-killing profile different from those of established platinum drugs, as well as a cationic complexes form monofunctional adducts on DNA that do not significantly distort the duplex, yet efficiently block transcription.
The rediscovery of platinum-based cancer therapy
New findings related to sensitivity and resistance to these drugs as well as recent advances in platinum drug development are discussed, including genome-wide functional screening approaches have revealed interesting insights into Pt drug uptake.
Current Concepts in the Use of Cisplatin: A Historical Perspective and Its Recent Advances in the Treatment of Non-Small Cell Lung Cancer
An overview of the current state of knowledge and clinical experience of cisplatin specifically highlighting its historical background, mechanism of action, development of tumor resistance and strategies to overcome its resistance in the treatment of cancer is provided.
New-generation platinum agents for solid tumors.
The clinical development of platinum agents to date is reviewed and the role of platinum agent in the treatment of cancer in the near future is speculated.
Rational design of multi-targeting ruthenium- and platinum-based anticancer complexes
This review systematically discusses the recent progress in the development of platinum- and ruthenium-based anticancer agents, in particular the rational design of platinum and r Ruthenium complexes with multi-targeting features.
Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release.
There exists a need to develop alternative strategies to effectively deliver platinum drugs to the tumor, with fewer side effects, because many tumors display inherent or acquired resistance to platinum-based therapies.
Beyond platinums: gold complexes as anticancer agents.
Gold(III)-peptide dithiocarbamato derivatives are designed which combine both the antitumor properties and reduced side-effects of the previously reported gold(III) analogues with enhanced bioavailability and tumor selectivity achieved by exploiting peptide transporters.


Cellular and molecular pharmacology of oxaliplatin.
The differences between oxaliplatin and cisplatin in terms of their spectrum of activity and adduct formation are described and molecular and cellular experimental data that potentially explain them are discussed, with particular emphasis on the differential role of DNA repair mechanisms.
Cellular accumulation of the anticancer agent cisplatin: a review.
This paper reviews the existing data on the mechanism of DDP accumulation and develops the postulate that some component of transport occurs through a gated ion channel.
Overcoming Resistance to Platinum Therapy in Patients with Advanced Cancer
From numerous studies of cancer cell lines in vitro, it is apparent that tumor resistance to cisplatin may arise through two general mechanisms: one preventing sufficient platinum from binding to DNA, and a second whereby platinum-DNA damage does not result in cell death.
Satraplatin: an orally available platinum analog for the treatment of cancer
  • H. Choy
  • Medicine, Biology
    Expert review of anticancer therapy
  • 2006
Availability of an active oral platinum agent, such as satraplatin, with few of the serious toxicities associated with traditional intravenous platinum compounds makes satra platin an alternative to other platinum agents and a new treatment option in the oncologist’s armamentarium.
An update on satraplatin: the first orally available platinum anticancer drug
  • L. Kèlland
  • Medicine, Biology
    Expert opinion on investigational drugs
  • 2000
These clinical studies with satraplatin indicate that oral platinum-based chemotherapy is feasible and, as predicted from the mouse studies, myelosuppression as the dose-limiting effect (neutropoenia and thrombocytopoenia).
Preclinical studies identifying carboplatin as a viable cisplatin alternative.
  • K. Harrap
  • Chemistry
    Cancer treatment reviews
  • 1985
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
This new class of sterically hindered platinum compound, selected for clinical trial in 1997, may therefore elicit improved clinical response in intrinsically and acquired cisplatin-resistant tumours in the clinic.